Launch metrics for Eli Lilly and Company’s GIP/GLP-1 analog Mounjaro (tirzepatide) in type 2 diabetes are exceeding expectations to this point, and the pharma reported during its 1 November earnings call that commercial coverage in the US increased significantly during the third quarter. Perhaps mindful of the supply issues faced by competitor Novo Nordisk A/S with Ozempic/Wegovy (semaglutide), Lilly is trying to prepare for high demand for the product in two major indications ahead of the planned submission for obesity in 2023.
[Sidebar#SC146825]








